Allarity Therapeutics
ALLR
6 hedge funds and large institutions have $516K invested in Allarity Therapeutics in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
1,447% more capital invested
Capital invested by funds: $33.3K → $516K (+$482K)
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
200% more funds holding
Funds holding: 2 → 6 (+4)
0.04% more ownership
Funds ownership: 0% → 0.04% (+0.04%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$768K |
| 2 |
AC
Armistice Capital
New York
|
+$557K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$56.4K |
| 4 |
VF
Virtu Financial
New York
|
+$55.1K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$26.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$23.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $268K | +$768K | +599 | New |
|
|
AC
2
Armistice Capital
New York
| $195K | +$557K | +435 | New |
|
|
3
Citadel Advisors
Miami,
Florida
| $19.6K | +$56.4K | +44 | New |
|
|
VF
4
Virtu Financial
New York
| $19K | +$55.1K | +43 | New |
|
|
TSS
5
Two Sigma Securities
New York
| $9.4K | +$26.9K | +21 | New |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $4.18K | +$8.97K | +7 | +350% |
|
7
Wells Fargo
San Francisco,
California
| $4 | – | – | – |
|
|
8
UBS Group
Zurich,
Switzerland
| – | -$23.9K | -6 | Closed |
|
ALLR Hedge Fund Activity: Q3 2023 in Review
6 of the 6,304 institutional investors tracked by Wall St. Rank reported a position in Allarity Therapeutics (ALLR) for Q3 2023, worth a combined $516K — up 1,447% from $33.3K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ALLR positions and 1 closed out — a net gain of 4 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $768K. The largest seller was UBS Group, exiting entirely with an estimated $23.9K sold.
- 6 institutional investors held Allarity Therapeutics (ALLR) as of Q3 2023, up from 2 in Q2 2023.
- Funds reported $516K of Allarity Therapeutics stock for Q3 2023, up 1,447% quarter-over-quarter.
- 5 funds opened new Allarity Therapeutics positions in Q3 2023 and 1 closed out, a net change of +4 holders.
- The largest Allarity Therapeutics buyer in Q3 2023 was Sabby Management, an estimated $768K added.
- The largest Allarity Therapeutics seller in Q3 2023 was UBS Group, an estimated $23.9K sold.
Based on aggregated 13F filings for Q3 2023.